285 related articles for article (PubMed ID: 21917395)
1. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
3. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
J Clin Microbiol; 2011 Nov; 49(11):3800-4. PubMed ID: 21900519
[TBL] [Abstract][Full Text] [Related]
4. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
[TBL] [Abstract][Full Text] [Related]
7. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
9. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method.
Cejudo MA; Gallego AG; Lacasa EC; Aller AI; Romero A; García JP; Andrés GQ; Martín-Mazuelos E
Med Mycol; 2010 Aug; 48(5):710-9. PubMed ID: 20109092
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
14. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Doern GV; Diekema DJ
J Clin Microbiol; 2005 May; 43(5):2163-7. PubMed ID: 15872236
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
16. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
[TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.
Pfaller MA; Diekema DJ; Procop GW; Wiederhold NP
J Clin Microbiol; 2014 Jun; 52(6):2126-30. PubMed ID: 24719450
[TBL] [Abstract][Full Text] [Related]
19. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
20. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
Pfaller MA; Diekema DJ; Ghannoum MA; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Espinel-Ingroff A; Fowler CL; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Sheehan DJ; Walsh TJ;
J Clin Microbiol; 2009 Oct; 47(10):3142-6. PubMed ID: 19692559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
